At PharmaVentures, a data room is used as a location to store essential documents that are needed during an M&A or Divestment transaction. It is an essential part of the due diligence process which interested buyers access prior to closing a transaction. We routinely use Virtual Data Rooms (VDR) from third-party providers of which there are many. All provide similar functionality but three essential features are the ability to permission document access to an individual user level, feedback on user activity, and a copy of all activity that took place in the VDR as an audit trail.
Haematological malignancies are types of cancers affecting blood, bone marrow and lymph nodes. Broadly speaking, there are three major types of blood cancers: leukaemia, lymphoma and myeloma. Of these, the most common blood cancer types include non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML) and multiple myeloma (MM). In the US, a newly diagnosed blood cancer patient is reported every three minutes, and new cases of blood cancers account for approximately 10% of all new cancer diagnoses. Also, an estimated 1.3 million people in the US are either living with or are in remission from blood cancer. Scientific and technological advances have led to a significant improvement in five-year relative survival rates for blood cancers, having more than doubled for lymphoma and more than quadrupled for myeloma and leukaemia over the last 50 years.
The evolving therapeutic landscape in haematologic malignancies
As you are aware PharmaVentures is a sector focused advisory firm and we are at the forefront of deal-making activity in the pharmaceutical, biotech, medtech and service sector industries such as CROs and CDMOs. Given the current backdrop and challenges facing companies executing live transactions or contemplating entering acquisition or divestment processes, we thought it may be useful to share with you our thoughts on the current deal-making environment and what we see in the ‘trenches’ of ongoing processes for our clients.
M&A in COVID-19 environment and beyond Keep your perspective
The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals.
